학술논문
A bibliometric analysis of HER2-positive breast cancer: 1987-2024.
Document Type
Academic Journal
Author
Ali-Thompson S; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; Daly GR; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; Department of Surgery, Beaumont Hospital, Dublin, Ireland.; Dowling GP; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; Department of Surgery, Beaumont Hospital, Dublin, Ireland.; Kilkenny C; Department of Surgery, Beaumont Hospital, Dublin, Ireland.; Cox L; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; McGrath J; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; AlRawashdeh MM; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; Naidoo S; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; Power C; Department of Surgery, Beaumont Hospital, Dublin, Ireland.; Hill ADK; Department of Surgery, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences (RCSI), Dublin, Ireland.; Department of Surgery, Beaumont Hospital, Dublin, Ireland.
Source
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2234-943X
Abstract
Aim: The overamplification of human epidermal growth factor (HER2) in breast cancer (BC) has been the subject of numerous research publications since its discovery in 1987. This is the first bibliometric analysis (BA) conducted on HER2-positive (HER2+) BC. The purpose of this BA is to analyze the published research on HER2+ BC from 1987 to 2024, highlighting the most significant scientific literature, as well as the main contributing authors and journals, and evaluating the impact of clinical and lab-based publications on HER2+ BC research.
Methods: The Web of Science Core Collection (WoSCC) was searched using the terms "Breast cancer" OR "Breast carcinoma" OR "Breast tumor" AND "HER2 positive" OR "HER2+". The search was limited by publication year (1987-2024) and only full English articles were included. WoS returned 7,469 relevant results, and from this dataset, a bibliometric analysis was conducted using the "analyze results" and "journal citation report" functions in WoS and the VOSviewer 1.6.16 software to generate bibliographic coupling and co-citation analysis of authors.
Results: The analysis encompassed a total of 7,469 publications, revealing a notable increase in the annual number of publications, particularly in recent years. The United States, China, Italy, Germany, and Spain were the top five most prolific countries. The top five significant institutions that published HER2+ research were the University of Texas System, Unicancer, UTMD Anderson Cancer Center, Harvard University, and University of California System. Breast Cancer Research and Treatment , Clinical Cancer Research , and Clinical Breast Cancer were the top three notable journals with the highest number of HER2+ BC publications. Dennis Slamon (Nc = 45,411, H-index = 51) and Jose Baselga (Nc = 32,592, H-index = 55) were the most prolific authors. Evolving research topics include anti-HER2 therapy in the neoadjuvant setting, treatment of metastatic HER2+ BC, and overcoming therapy resistance.
Conclusion: This study provides an overview of HER2+ BC research published over the past three decades. It provides insight into the most cited papers and authors, and the core journals, and identifies new trends. These manuscripts have had the highest impact in the field and reflect the continued evolution of HER2 as a therapeutic target in BC.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Ali-Thompson, Daly, Dowling, Kilkenny, Cox, McGrath, AlRawashdeh, Naidoo, Power and Hill.)
Methods: The Web of Science Core Collection (WoSCC) was searched using the terms "Breast cancer" OR "Breast carcinoma" OR "Breast tumor" AND "HER2 positive" OR "HER2+". The search was limited by publication year (1987-2024) and only full English articles were included. WoS returned 7,469 relevant results, and from this dataset, a bibliometric analysis was conducted using the "analyze results" and "journal citation report" functions in WoS and the VOSviewer 1.6.16 software to generate bibliographic coupling and co-citation analysis of authors.
Results: The analysis encompassed a total of 7,469 publications, revealing a notable increase in the annual number of publications, particularly in recent years. The United States, China, Italy, Germany, and Spain were the top five most prolific countries. The top five significant institutions that published HER2+ research were the University of Texas System, Unicancer, UTMD Anderson Cancer Center, Harvard University, and University of California System. Breast Cancer Research and Treatment , Clinical Cancer Research , and Clinical Breast Cancer were the top three notable journals with the highest number of HER2+ BC publications. Dennis Slamon (Nc = 45,411, H-index = 51) and Jose Baselga (Nc = 32,592, H-index = 55) were the most prolific authors. Evolving research topics include anti-HER2 therapy in the neoadjuvant setting, treatment of metastatic HER2+ BC, and overcoming therapy resistance.
Conclusion: This study provides an overview of HER2+ BC research published over the past three decades. It provides insight into the most cited papers and authors, and the core journals, and identifies new trends. These manuscripts have had the highest impact in the field and reflect the continued evolution of HER2 as a therapeutic target in BC.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Ali-Thompson, Daly, Dowling, Kilkenny, Cox, McGrath, AlRawashdeh, Naidoo, Power and Hill.)